Some of the names on the move ahead of the open.» Read More
U.S. stock index futures pointed to a higher open, ahead of first quarter earnings from companies including Twitter and eBay.
At the heart of Pfizer's pursuit of AstraZeneca is a shortage of products in its research pipeline, aggravated by a series of disappointing drug launches.
Argus Research's John Eade weighs in on growing M&A in the pharma space.
These companies have been shrinking either due to dropping demand, evaporating pricing power or by reducing their size.
Investors will navigate a Fed meeting, an earnings flood, and significant economic data, but traders agree global tensions will continue to dominate the market.
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound takeover approach was rejected.
With the wipeout in growth stocks, many investors turned their attention to big-cap and value names, and the trend is expected to continue.
LONDON, April 21- Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise.
ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.
LOS ANGELES/ LONDON April 11- Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.
WASHINGTON, April 10- The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.
April 10- A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.
April 10- A two-drug combination being tested by Merck& Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.
LONDON, April 9- The World Health Organisation wants a "concerted effort" to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide.
April 4- Amgen Inc said its experimental drug to treat a deadly form of skin cancer did not significantly improve overall survival rates in patients enrolled in a late-stage study.
LONDON, April 2- GlaxoSmithKline Plc has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit.
March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 8 percent, Amgen Inc dropped 3 percent and Celgene Corp lost 3.7 percent.
CAIRO/ LONDON, March 21- Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price.
March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 6 percent, Amgen Inc dropped 2.5 percent and Celgene Corp was down 2 percent.